Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
12,214
archived clinical trials in
Women's Studies

Preservation of Ovarian Function Via LOT in Squamous Cell Carcinoma of the Cervix
Preservation of Ovarian Function Via Laparoscopic Transposition in Patients With Locally Advanced Squamous Cell Carcinoma of the Cervix
Status: Enrolling
Updated:  9/30/2015
University of Wisconsin
mi
from
Madison, WI
Preservation of Ovarian Function Via LOT in Squamous Cell Carcinoma of the Cervix
Preservation of Ovarian Function Via Laparoscopic Transposition in Patients With Locally Advanced Squamous Cell Carcinoma of the Cervix
Status: Enrolling
Updated: 9/30/2015
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Laparoscopic Sentinel Lymph Node Localization in Operable Cervix Cancer
Laparoscopic Sentinel Lymph Node Localization in Patients With Operable Cervical Cancer - A Pilot Study
Status: Enrolling
Updated:  9/30/2015
University of Wisconsin
mi
from
Madison, WI
Laparoscopic Sentinel Lymph Node Localization in Operable Cervix Cancer
Laparoscopic Sentinel Lymph Node Localization in Patients With Operable Cervical Cancer - A Pilot Study
Status: Enrolling
Updated: 9/30/2015
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters
Status: Enrolling
Updated:  10/1/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters
Status: Enrolling
Updated: 10/1/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated:  10/1/2015
Geauga Regional Hospital
mi
from
Cleveland, OH
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated: 10/1/2015
Geauga Regional Hospital
mi
from
Cleveland, OH
Click here to add this to my saved trials
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated:  10/1/2015
Lake/University Ireland Cancer Center
mi
from
Cleveland, OH
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated: 10/1/2015
Lake/University Ireland Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated:  10/1/2015
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated: 10/1/2015
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated:  10/1/2015
University Suburban Health Center
mi
from
Cleveland, OH
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated: 10/1/2015
University Suburban Health Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated:  10/1/2015
UHHS Chagrin Highlands Medical Center
mi
from
Cleveland, OH
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated: 10/1/2015
UHHS Chagrin Highlands Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated:  10/1/2015
Southwest General Health Center
mi
from
Cleveland, OH
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated: 10/1/2015
Southwest General Health Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated:  10/1/2015
UHHS Westlake Medical Center
mi
from
Cleveland, OH
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated: 10/1/2015
UHHS Westlake Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated:  10/1/2015
Mercy Cancer Center at Mercy Medical Center
mi
from
Cleveland, OH
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated: 10/1/2015
Mercy Cancer Center at Mercy Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Human Papilloma Virus Infection in HIV-Positive Indian Men Who Have Sex With Men
HPV Infection in Indian HIV-Seropositive Men Who Have Sex With Men (MSM)
Status: Enrolling
Updated:  10/1/2015
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Human Papilloma Virus Infection in HIV-Positive Indian Men Who Have Sex With Men
HPV Infection in Indian HIV-Seropositive Men Who Have Sex With Men (MSM)
Status: Enrolling
Updated: 10/1/2015
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Folic Acid Clinical Trial for the Prevention of Cervical Cancer
HPV Clearance by Folic Acid Supplementation (FACT for HPV)
Status: Enrolling
Updated:  10/6/2015
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
Folic Acid Clinical Trial for the Prevention of Cervical Cancer
HPV Clearance by Folic Acid Supplementation (FACT for HPV)
Status: Enrolling
Updated: 10/6/2015
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Treatment of Vitamin D Insufficiency
Treatment of Vitamin D Insufficiency
Status: Enrolling
Updated:  10/6/2015
University of Wisconsin School of Medicine and Public Health
mi
from
Madison, WI
Treatment of Vitamin D Insufficiency
Treatment of Vitamin D Insufficiency
Status: Enrolling
Updated: 10/6/2015
University of Wisconsin School of Medicine and Public Health
mi
from
Madison, WI
Click here to add this to my saved trials
Stage Matched Intervention to Increase Dual Method Use
Stage Matched Intervention to Increase Dual Method Use
Status: Enrolling
Updated:  10/6/2015
Women and Infants Hospital
mi
from
Providence, RI
Stage Matched Intervention to Increase Dual Method Use
Stage Matched Intervention to Increase Dual Method Use
Status: Enrolling
Updated: 10/6/2015
Women and Infants Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer
A Biobehavioral Intervention for Patients With Gynecologic or Breast Cancer Recurrence
Status: Enrolling
Updated:  10/8/2015
Ohio State University Medical Center
mi
from
Columbus, OH
Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer
A Biobehavioral Intervention for Patients With Gynecologic or Breast Cancer Recurrence
Status: Enrolling
Updated: 10/8/2015
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Massage To Improve Uterine Artery Blood Flow
Massage to Reduce Intrauterine Artery Resistance, Prematurity and Low Birthweight
Status: Enrolling
Updated:  10/8/2015
University of Miami
mi
from
Miami, FL
Massage To Improve Uterine Artery Blood Flow
Massage to Reduce Intrauterine Artery Resistance, Prematurity and Low Birthweight
Status: Enrolling
Updated: 10/8/2015
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia
An Adaptive Multicentre, Randomized, Partially Double-blind, Placebo-controlled Study to Assess the Safety, PK and PD/Efficacy of RLX030 in Women With Pre-eclampsia
Status: Enrolling
Updated:  10/12/2015
Novartis Investigative Site
mi
from
Mobile, AL
Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia
An Adaptive Multicentre, Randomized, Partially Double-blind, Placebo-controlled Study to Assess the Safety, PK and PD/Efficacy of RLX030 in Women With Pre-eclampsia
Status: Enrolling
Updated: 10/12/2015
Novartis Investigative Site
mi
from
Mobile, AL
Click here to add this to my saved trials
Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia
An Adaptive Multicentre, Randomized, Partially Double-blind, Placebo-controlled Study to Assess the Safety, PK and PD/Efficacy of RLX030 in Women With Pre-eclampsia
Status: Enrolling
Updated:  10/12/2015
Novartis Investigative Site
mi
from
Lexington, KY
Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia
An Adaptive Multicentre, Randomized, Partially Double-blind, Placebo-controlled Study to Assess the Safety, PK and PD/Efficacy of RLX030 in Women With Pre-eclampsia
Status: Enrolling
Updated: 10/12/2015
Novartis Investigative Site
mi
from
Lexington, KY
Click here to add this to my saved trials
Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia
An Adaptive Multicentre, Randomized, Partially Double-blind, Placebo-controlled Study to Assess the Safety, PK and PD/Efficacy of RLX030 in Women With Pre-eclampsia
Status: Enrolling
Updated:  10/12/2015
Novartis Investigative Site
mi
from
Louisville, KY
Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia
An Adaptive Multicentre, Randomized, Partially Double-blind, Placebo-controlled Study to Assess the Safety, PK and PD/Efficacy of RLX030 in Women With Pre-eclampsia
Status: Enrolling
Updated: 10/12/2015
Novartis Investigative Site
mi
from
Louisville, KY
Click here to add this to my saved trials
Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia
An Adaptive Multicentre, Randomized, Partially Double-blind, Placebo-controlled Study to Assess the Safety, PK and PD/Efficacy of RLX030 in Women With Pre-eclampsia
Status: Enrolling
Updated:  10/12/2015
Novartis Investigative Site
mi
from
Galveston, TX
Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia
An Adaptive Multicentre, Randomized, Partially Double-blind, Placebo-controlled Study to Assess the Safety, PK and PD/Efficacy of RLX030 in Women With Pre-eclampsia
Status: Enrolling
Updated: 10/12/2015
Novartis Investigative Site
mi
from
Galveston, TX
Click here to add this to my saved trials
Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia
An Adaptive Multicentre, Randomized, Partially Double-blind, Placebo-controlled Study to Assess the Safety, PK and PD/Efficacy of RLX030 in Women With Pre-eclampsia
Status: Enrolling
Updated:  10/12/2015
Novartis Investigative Site
mi
from
Modena,
Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia
An Adaptive Multicentre, Randomized, Partially Double-blind, Placebo-controlled Study to Assess the Safety, PK and PD/Efficacy of RLX030 in Women With Pre-eclampsia
Status: Enrolling
Updated: 10/12/2015
Novartis Investigative Site
mi
from
Modena,
Click here to add this to my saved trials
Pelvic Floor Physical Therapy-Biomarkers Project
Women's Urology Center-Physical Therapy-Biomarkers Project
Status: Enrolling
Updated:  10/13/2015
Beaumont Women's Urology Center
mi
from
Royal Oak, MI
Pelvic Floor Physical Therapy-Biomarkers Project
Women's Urology Center-Physical Therapy-Biomarkers Project
Status: Enrolling
Updated: 10/13/2015
Beaumont Women's Urology Center
mi
from
Royal Oak, MI
Click here to add this to my saved trials
The Valve of Hyaluronic Binding Selection (PICSI) in Improving IVF Outcome
Status: Enrolling
Updated:  10/13/2015
The Continuum Reproductive Center
mi
from
New York, NY
The Valve of Hyaluronic Binding Selection (PICSI) in Improving IVF Outcome
Status: Enrolling
Updated: 10/13/2015
The Continuum Reproductive Center
mi
from
New York, NY
Click here to add this to my saved trials
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Montgomery Women's Health Associates, PC
mi
from
Montgomery, AL
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Montgomery Women's Health Associates, PC
mi
from
Montgomery, AL
Click here to add this to my saved trials
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
East Valley Family Physicians PLC
mi
from
Chandler, AZ
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
East Valley Family Physicians PLC
mi
from
Chandler, AZ
Click here to add this to my saved trials
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Genesis Center For Clinical Research
mi
from
San Diego, CA
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Genesis Center For Clinical Research
mi
from
San Diego, CA
Click here to add this to my saved trials
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Apex Research Institute
mi
from
Santa Ana, CA
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Apex Research Institute
mi
from
Santa Ana, CA
Click here to add this to my saved trials
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Downtown Women's Health Care
mi
from
Denver, CO
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Downtown Women's Health Care
mi
from
Denver, CO
Click here to add this to my saved trials
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Chase Medical Research, LLC
mi
from
Waterbury, CT
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Chase Medical Research, LLC
mi
from
Waterbury, CT
Click here to add this to my saved trials
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Visions Clinical Research
mi
from
Boynton Beach, FL
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Visions Clinical Research
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Women's Medical Research Group, LLC
mi
from
Clearwater, FL
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Women's Medical Research Group, LLC
mi
from
Clearwater, FL
Click here to add this to my saved trials
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Altus Research
mi
from
Lake Worth, FL
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Altus Research
mi
from
Lake Worth, FL
Click here to add this to my saved trials
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Anchor Research Center
mi
from
Naples, FL
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Anchor Research Center
mi
from
Naples, FL
Click here to add this to my saved trials
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Comprehensive Clinical Trials
mi
from
West Palm Beach, FL
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Comprehensive Clinical Trials
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Soapstone Center for Clinical Research
mi
from
Decatur, GA
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Soapstone Center for Clinical Research
mi
from
Decatur, GA
Click here to add this to my saved trials
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Mount Vernon Clinical Research, LLC
mi
from
Sandy Springs, GA
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Mount Vernon Clinical Research, LLC
mi
from
Sandy Springs, GA
Click here to add this to my saved trials
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Women's Clinic of Lincoln, PC
mi
from
Lincoln, NE
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Women's Clinic of Lincoln, PC
mi
from
Lincoln, NE
Click here to add this to my saved trials
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Phoenix Ob-Gyn Associates, LLC
mi
from
Moorestown, NJ
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Phoenix Ob-Gyn Associates, LLC
mi
from
Moorestown, NJ
Click here to add this to my saved trials
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Hawthorne Research
mi
from
Greensboro, NC
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Hawthorne Research
mi
from
Greensboro, NC
Click here to add this to my saved trials
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Hawthorne Medical Research, Inc.
mi
from
Winston-Salem, NC
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Hawthorne Medical Research, Inc.
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Columbus Center for Women's Health Research
mi
from
Columbus, OH
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Columbus Center for Women's Health Research
mi
from
Columbus, OH
Click here to add this to my saved trials
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
The Clinical Trial Center, LLC
mi
from
Jenkintown, PA
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
The Clinical Trial Center, LLC
mi
from
Jenkintown, PA
Click here to add this to my saved trials
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Clinical Trials Research Services, LLC
mi
from
Pittsburgh, PA
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Clinical Trials Research Services, LLC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
SC Clinical Research Center, LLC
mi
from
Columbia, SC
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
SC Clinical Research Center, LLC
mi
from
Columbia, SC
Click here to add this to my saved trials
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Chattanooga Medical Research, LLC
mi
from
Chattanooga, TN
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Chattanooga Medical Research, LLC
mi
from
Chattanooga, TN
Click here to add this to my saved trials
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Clinical Research Associates
mi
from
Nashville, TN
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Clinical Research Associates
mi
from
Nashville, TN
Click here to add this to my saved trials
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Virginia Women's Center
mi
from
Richmond, VA
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Virginia Women's Center
mi
from
Richmond, VA
Click here to add this to my saved trials
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
North Spokane Women's Clinic Research
mi
from
Spokane, WA
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
North Spokane Women's Clinic Research
mi
from
Spokane, WA
Click here to add this to my saved trials
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated:  10/14/2015
Meridien Research
mi
from
Brooksville, FL
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Enrolling
Updated: 10/14/2015
Meridien Research
mi
from
Brooksville, FL
Click here to add this to my saved trials